Health ❯ Healthcare ❯ Patient Care

Treatment Options

Oral Medications Innovative Therapies Subcutaneous Administration Personalized Medicine Targeted Therapy Combination Therapy Chemotherapy Metastatic Cancer Endocrine Therapy Cognitive Impairment

5 ARTICLES

5d ago

Lilly Says Foundayo Outperforms Novo’s Oral Semaglutide in Indirect Diabetes Comparison

Lilly’s EASD presentation claims larger weight loss and A1C drops for Foundayo while leaving regulators to judge the limits of indirect trial comparisons.

16 ARTICLES

6d ago

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Adults With Type 2 Diabetes

3 ARTICLES

last wk.

aTyr Pharma Secures FDA Agreement on Phase 3 Protocol for Efzofitimod in Pulmonary Sarcoidosis

8 ARTICLES

last wk.

FDA Advisory Panel Reviews GRAIL’s Galleri Multi‑Cancer Blood Test

3 ARTICLES

last wk.

Amgen’s Dazodalibep Meets Primary Goal in Phase 3 Sjögren’s Trial

3 ARTICLES

3w ago

AstraZeneca’s Etcamah Falls Short in Pivotal SERENA‑4 Breast Cancer Trial

8 ARTICLES

3w ago

AstraZeneca's Tozorakimab Cuts COPD Flare‑Ups in Two Phase 3 Trials

9 ARTICLES

4w ago

FDA Clears Pancreatic Drug That Shows Early Promise in RAS‑Mutant Lung Cancer

4 ARTICLES

4w ago

Teva’s Experimental Antibody Prevents Gluten‑Triggered Intestinal Damage in Mid‑Stage Celiac Trial

5 ARTICLES

4w ago

FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera

9 ARTICLES

last mo.

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

8 ARTICLES

last mo.

FDA Approves Lisraya as First Oral Treatment for Adult Dermatomyositis

56 ARTICLES

last mo.

FDA Clears First Broadly RAS‑Targeting Pill for Advanced Pancreatic Cancer

3 ARTICLES

last mo.

FDA Approves Bixlenvo, a Once‑Daily Single‑Pill HIV Regimen

5 ARTICLES

last mo.

FDA Approves Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer

4 ARTICLES

last mo.

FDA Expands Approval of J&J’s Imaavy to Treat Warm Autoimmune Hemolytic Anemia

7 ARTICLES

last mo.

Anvisa and Roche Cancel Brazil’s Conditional Approval for Elevidys

Treatment Options

Lilly Says Foundayo Outperforms Novo’s Oral Semaglutide in Indirect Diabetes Comparison

Phase 3 Trials at ASTRO Strengthen Case for Focused, Short‑Course Radiation

Near‑Daily Cannabis Use Linked to Higher Seizure Burden in Small EMU Study

FDA Approves Juvmo as First D1/D5 Agonist for Parkinson’s Disease

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Adults With Type 2 Diabetes

aTyr Pharma Secures FDA Agreement on Phase 3 Protocol for Efzofitimod in Pulmonary Sarcoidosis

FDA Advisory Panel Reviews GRAIL’s Galleri Multi‑Cancer Blood Test

Amgen’s Dazodalibep Meets Primary Goal in Phase 3 Sjögren’s Trial

AstraZeneca’s Etcamah Falls Short in Pivotal SERENA‑4 Breast Cancer Trial

AstraZeneca's Tozorakimab Cuts COPD Flare‑Ups in Two Phase 3 Trials

Never miss stories about

Treatment Options

FDA Clears Pancreatic Drug That Shows Early Promise in RAS‑Mutant Lung Cancer

Teva’s Experimental Antibody Prevents Gluten‑Triggered Intestinal Damage in Mid‑Stage Celiac Trial

FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

FDA Approves Lisraya as First Oral Treatment for Adult Dermatomyositis

FDA Clears First Broadly RAS‑Targeting Pill for Advanced Pancreatic Cancer

FDA Approves Bixlenvo, a Once‑Daily Single‑Pill HIV Regimen

FDA Approves Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer

FDA Expands Approval of J&J’s Imaavy to Treat Warm Autoimmune Hemolytic Anemia

Anvisa and Roche Cancel Brazil’s Conditional Approval for Elevidys

Never miss stories about

Treatment Options